BRIEF-Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis

Reuters
Jun 05
BRIEF-Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis

Kiniksa Pharmaceuticals International PLC KNSA.O:

  • KINIKSA PHARMACEUTICALS ANNOUNCES TRIAL DESIGN OF PLANNED PHASE 2/3 CLINICAL TRIAL OF KPL-387 IN RECURRENT PERICARDITIS

  • KINIKSA PHARMACEUTICALS INTERNATIONAL PLC - TO INITIATE PHASE 2/3 TRIAL OF KPL-387 IN MID-2025

  • KINIKSA PHARMACEUTICALS INTERNATIONAL PLC: KPL-387 PHASE 2 DATA EXPECTED IN 2H 2026

Source text: ID:nGNXbqNj3Y

Further company coverage: KNSA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10